Ionis Pharmaceuticals (IONS) EBIT: 2009-2025
Historic EBIT for Ionis Pharmaceuticals (IONS) over the last 17 years, with Sep 2025 value amounting to -$160.2 million.
- Ionis Pharmaceuticals' EBIT fell 7.75% to -$160.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$278.0 million, marking a year-over-year increase of 24.93%. This contributed to the annual value of -$475.1 million for FY2024, which is 34.31% down from last year.
- Ionis Pharmaceuticals' EBIT amounted to -$160.2 million in Q3 2025, which was down 214.57% from $139.8 million recorded in Q2 2025.
- In the past 5 years, Ionis Pharmaceuticals' EBIT registered a high of $220.6 million during Q4 2021, and its lowest value of -$208.0 million during Q4 2022.
- Moreover, its 3-year median value for EBIT was -$114.1 million (2023), whereas its average is -$90.5 million.
- As far as peak fluctuations go, Ionis Pharmaceuticals' EBIT soared by 1,073.36% in 2021, and later slumped by 1,710.21% in 2024.
- Quarterly analysis of 5 years shows Ionis Pharmaceuticals' EBIT stood at $220.6 million in 2021, then tumbled by 194.30% to -$208.0 million in 2022, then spiked by 97.06% to -$6.1 million in 2023, then crashed by 1,710.21% to -$110.8 million in 2024, then declined by 7.75% to -$160.2 million in 2025.
- Its EBIT was -$160.2 million in Q3 2025, compared to $139.8 million in Q2 2025 and -$146.9 million in Q1 2025.